Tearsheet
Investment Highlights Market Valuation Price Chart Business Description Interactive Breakdown Latest Trefis Analyses Better Bets vs. EXAS Recent Active Movers More From Trefis Peer Financials Peer Growth & Margins Peer Valuation Peer Returns Peer Analyses FDIC Bank Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Insider Activity Industry Resource Links External Quote Links

Exact Sciences (EXAS)

Market Price (9/18/2025): $51.99 | Market Cap: $9.8 Bil
Sector: Health Care | Industry: Life Sciences Tools & Services

Exact Sciences (EXAS)

Market Price (9/18/2025): $51.99
Market Cap: $9.8 Bil
Sector: Health Care
Industry: Life Sciences Tools & Services

Investment Highlights

0 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 10%		 Weak multi-year price returns
2Y Excs Rtn is -81%, 3Y Excs Rtn is -35%		 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -151 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -5.1%
1 Low stock price volatility
Vol 12M is 49%		  Expensive valuation multiples
P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 32x
2   Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -15%
0 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 10%
1 Low stock price volatility
Vol 12M is 49%
2 Weak multi-year price returns
2Y Excs Rtn is -81%, 3Y Excs Rtn is -35%
3 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -151 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -5.1%
4 Expensive valuation multiples
P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 32x
5 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -15%

Market Valuation

 9/18/252024202320222021
Share Price CYE$51.99$56.19$73.98$49.51$77.83
Market Cap CYE ($ Bil)9.810.413.48.813.4
Total Debt ($ Bil)2.52.82.62.42.4
Total Cash ($ Bil)0.91.00.80.61.0
Enterprise Value ($ Bil)11.513.216.011.215.8
Valuation Ratios     
P/S TTM3.33.85.34.27.5
P/EBIT TTM-9.9-10.3-75.2-14.1-16.1
P/E TTM-9.8-10.1-65.3-14.0-22.4
Sector Ratios     
P/S TTM (Sector)3.83.64.14.57.3
P/EBIT TTM (Sector)-1.6-1.3-1.4-1.3-2.9
P/E TTM (Sector)-1.8-1.5-1.5-1.3-2.9
 9/18/2520242023
Share Price CYE$51.99$56.19$73.98
Market Cap CYE ($ Bil)9.810.413.4
Total Debt ($ Bil)2.52.82.6
Total Cash ($ Bil)0.91.00.8
Enterprise Value ($ Bil)11.513.216.0
Valuation Ratios   
P/S TTM3.33.85.3
P/EBIT TTM-9.9-10.3-75.2
P/E TTM-9.8-10.1-65.3
Sector Ratios   
P/S TTM (Sector)3.83.64.1
P/EBIT TTM (Sector)-1.6-1.3-1.4
P/E TTM (Sector)-1.8-1.5-1.5

Market Cap Chart

Business Description

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. Show more

Price Returns Compared

Expand for Detailed View

 202020212022202320242025Total [1]
Returns
EXAS Return43%-41%-36%49%-24%-7%-42%
Peers Return41%48%-28%-6%0%-20%13%
S&P 500 Return16%27%-19%24%23%12%104%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: TNDM, TMO, DHR, A, IQV. See EXAS Returns vs. Peers.
[3] 2025 data is for the year up to 9/17/2025 (YTD)

Better Bets than Exact Sciences (EXAS)

 EXASBetter Performance than EXAS
MetricValueIndustry (Life Sciences Tools & Services)
Rev Chg LTM12.6%NTRA (44.4%), GH (28.2%), IRTC (22.4%), WGS (48.7%), ATEC (26.3%)
Rev Chg 3Y Avg14.9%NTRA (39.7%), MEDP (20.4%), GH (25.6%), IRTC (22.1%), WGS (25.2%)
Op Mgn LTM-5.1%TMO (18.2%), DHR (18.4%), A (21.3%), IQV (14.4%), MTD (28.4%)
CFO/Rev LTM10.4%TMO (17.5%), DHR (25.7%), A (22.0%), IQV (16.7%), MTD (24.6%)
FCF/Rev LTM5.8%TMO (14.3%), DHR (20.2%), A (16.0%), IQV (12.8%), MTD (21.9%)
Total Yield-10.2%TMO (3.7%), DHR (2.5%), A (4.2%), IQV (3.9%), MTD (3.1%)
 EXASBetter Performance than EXAS
MetricValueAll Other Sectors
Rev Chg LTM12.6%NVDA (71.6%), MSFT (14.9%), GOOGL (13.1%), META (19.4%), AVGO (28.0%)
Rev Chg 3Y Avg14.9%NVDA (92.0%), AVGO (24.0%), BRK-B (16.6%), PLTR (25.7%), TM (15.2%)
Op Mgn LTM-5.1%NVDA (58.1%), MSFT (45.6%), AAPL (31.9%), GOOGL (32.7%), AMZN (11.4%)
CFO/Rev LTM10.4%NVDA (46.6%), MSFT (48.3%), AAPL (26.6%), GOOGL (36.0%), AMZN (18.1%)
FCF/Rev LTM5.8%NVDA (43.6%), MSFT (25.4%), AAPL (23.5%), GOOGL (18.0%), META (30.7%)
Total Yield-10.2%NVDA (2.1%), MSFT (3.3%), AAPL (3.2%), GOOGL (4.1%), AMZN (2.9%)

Latest Trefis Analyses

TitleTopicDate
0DASHBOARDS  
1Exact Sciences Earnings Notes  
2EXAS Shares Rally 16% In A Month: How Does the Competition Measure Up?Peer Comparison 
3Is The 25.9% Decline In Exact Sciences (EXAS) Stock A Dip Buying Opportunity?Actionable 
4EXAS Dip Buy Analysis  
5Exact Sciences (EXAS) Operating Cash Flow ComparisonFinancials 
6Exact Sciences (EXAS) Net Income ComparisonFinancials 
7Exact Sciences (EXAS) Operating Income ComparisonFinancials 
8Exact Sciences (EXAS) Revenue ComparisonFinancials 
9Day 0 of Loss Streak for Exact Sciences Stock with 0% Return (vs. -16% YTD) [12/2/2024]Notification 
10Exact Sciences vs. S&P500 CorrelationCorrelation 
11ARTICLES  
12EXAS Shares Tumbled 26%, Opportunity Or Trap? August 9th, 2025
13EXAS Looks Stronger Than TMO With 50% Return Potential July 31st, 2025
14Strong Revenue Trend Could Drive EXACT Sciences Corporation Stock To $160 June 17th, 2021

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1ECDAECD Automotive Design3347.2%307.9%
2BDSXBiodesix1090.6%-79.7%
3CLSDClearside Biomedical987.7%-74.7%
4ATHAAthira Pharma892.1%544.3%
5SDOTSadot690.6%-79.9%
6ATCHAtlasClear684.9%-83.1%
7HSDTHelius Medical Technologies232.1%-95.5%
8CHEKCheck-Cap222.2%134.4%
9APLMApollomics197.8%89.1%
10SPRCSciSparc147.0%1141.7%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1CURXCuranex Pharmaceuticals-80.5%148.4%
2ATYRaTyr Pharma-80.4%-71.7%
3NAKAKindly MD-70.2% 
4BNGOBionano Genomics-64.0%-89.8%
5XAGELongevity Health-57.6%-86.1%
6FAASDigiAsia-55.4%-88.0%
7ASSTStrive-54.5%650.3%
8VCIGVCI Global-51.0%-98.9%
9REXREX American Resources-50.7%44.3%
10RBNERobin Energy-42.6% 

1 Month Top Gainers

#TickerCompany1M RtnYTD Rtn
1PMIPicard Medical11931.7%11931.7%
2GIBOGIBO10714.0% 
3LNZALanzaTech Global8455.2%-86.3%
4GTIGraphjet Technology3998.4%-93.1%
5GWAVGreenwave Technology Solutions3582.8%-91.4%
6QMMMQMMM3409.6%8153.1%
7ECDAECD Automotive Design2715.2%307.9%
8OESXOrion Energy Systems1373.7%14.2%
9OPOceanPal1266.5%-95.6%
10BCTXBriaCell Therapeutics1032.4%-89.8%

1 Month Top Losers

#TickerCompany1M RtnYTD Rtn
1CJETChijet Motor-94.5%-96.0%
2STFSStar Fashion Culture-92.3%-97.9%
3ELPWElong Power-91.1%-76.9%
4NXTTNext Technology-90.1%-95.4%
5EPIXESSA Pharma-89.4%-8.9%
6NAKAKindly MD-88.1% 
7BINIBollinger Innovations-87.6%-100.0%
8JEM707 Cayman-87.4%-98.2%
9YAASYouxin Technology-83.3%-98.4%
10NEONNeonode-82.5%-51.0%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1ECDAECD Automotive Design3347.2%307.9%
2BDSXBiodesix1090.6%-79.7%
3CLSDClearside Biomedical987.7%-74.7%
4ATHAAthira Pharma892.1%544.3%
5SDOTSadot690.6%-79.9%
6ATCHAtlasClear684.9%-83.1%
7HSDTHelius Medical Technologies232.1%-95.5%
8CHEKCheck-Cap222.2%134.4%
9APLMApollomics197.8%89.1%
10SPRCSciSparc147.0%1141.7%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1CURXCuranex Pharmaceuticals-80.5%148.4%
2ATYRaTyr Pharma-80.4%-71.7%
3NAKAKindly MD-70.2% 
4BNGOBionano Genomics-64.0%-89.8%
5XAGELongevity Health-57.6%-86.1%
6FAASDigiAsia-55.4%-88.0%
7ASSTStrive-54.5%650.3%
8VCIGVCI Global-51.0%-98.9%
9REXREX American Resources-50.7%44.3%
10RBNERobin Energy-42.6% 

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Exact Sciences

Financials

EXASTNDMTMODHRAIQVMedian
NameExact Sc.Tandem D.Thermo F.Danaher Agilent .IQVIA  
Mkt Price52.3812.18472.64192.94126.72186.69156.70
Mkt Cap9.90.8178.7138.236.032.134.0
Rev LTM2,9401,00243,21124,0136,78815,70011,244
Op Inc LTM-151-1797,8604,4171,4442,2631,854
FCF LTM170-516,1704,8621,0882,0101,549
FCF 3Y Avg15-446,6625,7331,3081,8061,557
CFO LTM306107,5786,1691,4952,6172,056
CFO 3Y Avg166-28,2067,0131,6622,4332,047

Growth & Margins

EXASTNDMTMODHRAIQVMedian
NameExact Sc.Tandem D.Thermo F.Danaher Agilent .IQVIA  
Rev Chg LTM12.6%25.8%2.0%1.9%4.5%3.6%4.0%
Rev Chg 3Y Avg14.9%9.9%0.3%-2.6%0.8%3.6%2.2%
Rev Chg Q16.0%8.5%3.0%3.4%10.1%5.3%6.9%
QoQ Delta Rev Chg LTM4.0%1.9%0.7%0.8%2.4%1.3%1.6%
Op Mgn LTM-5.1%-17.9%18.2%18.4%21.3%14.4%16.3%
Op Mgn 3Y Avg-9.8%-24.9%17.4%21.6%21.5%13.7%15.6%
QoQ Delta Op Mgn LTM0.8%0.2%-0.1%-1.9%-0.1%-0.3%-0.1%
CFO/Rev LTM10.4%1.0%17.5%25.7%22.0%16.7%17.1%
CFO/Rev 3Y Avg6.0%-0.3%19.1%29.9%24.6%16.0%17.6%
FCF/Rev LTM5.8%-5.1%14.3%20.2%16.0%12.8%13.5%
FCF/Rev 3Y Avg0.2%-5.1%15.5%24.4%19.4%11.9%13.7%

Valuation

EXASTNDMTMODHRAIQVMedian
NameExact Sc.Tandem D.Thermo F.Danaher Agilent .IQVIA  
Mkt Cap9.90.8178.7138.236.032.134.0
P/S3.40.84.15.85.32.03.8
P/EBIT-10.0-4.221.331.723.814.417.8
P/E-9.8-4.027.140.529.525.926.5
P/CFO32.484.023.622.424.112.323.8
Total Yield-10.2%-25.2%3.7%2.5%4.2%3.9%3.1%
Dividend Yield0.0%0.0%0.0%0.0%0.8%0.0%0.0%
FCF Yield 3Y Avg0.3%-2.7%3.6%3.4%3.7%5.3%3.5%
D/E0.30.50.20.10.10.50.2
Net D/E0.20.20.20.10.10.40.2

Returns

EXASTNDMTMODHRAIQVMedian
NameExact Sc.Tandem D.Thermo F.Danaher Agilent .IQVIA  
1M Rtn16.2%12.4%-3.0%-7.7%7.3%-3.0%2.1%
3M Rtn0.1%-40.3%20.5%-0.6%9.9%20.7%5.0%
6M Rtn14.6%-40.9%-8.7%-8.0%4.1%-0.1%-4.0%
12M Rtn-23.0%-71.7%-22.3%-28.8%-7.7%-22.2%-22.6%
3Y Rtn33.5%-78.7%-11.9%-20.5%-0.3%-8.9%-10.4%
1M Excs Rtn13.8%10.0%-5.3%-10.0%4.9%-5.4%-0.2%
3M Excs Rtn-10.6%-49.6%10.9%-11.6%-0.9%10.8%-5.8%
6M Excs Rtn-0.9%-56.8%-26.7%-26.6%-14.2%-18.5%-22.6%
12M Excs Rtn-37.4%-89.6%-39.7%-46.6%-24.3%-39.1%-39.4%
3Y Excs Rtn-34.7%-139.5%-78.2%-85.5%-68.0%-78.2%-78.2%

Comparison Analyses

Financials

$ Mil | FY: 12/312025Q22025Q12024Q42024Q32024Q22024Q12023Q42023Q32023Q22023Q12022Q42022Q3
Period End6/30/20253/31/202512/31/20249/30/20246/30/20243/31/202412/31/20239/30/20236/30/20233/31/202312/31/20229/30/2022
Filing Date8/6/20255/1/20252/19/202511/5/20247/31/20245/8/20242/21/202411/1/20238/1/20235/9/20232/21/202311/3/2022
Key Financials Quarterly            
Total Revenue811707713709699638647628622602553523
Ebitda53-38-8152635-481060-26-27-76-100
Operating Income-2-90-38-21-18-102-687-76-77-115-132
Net Income-1-101-865-38-16-110-501-81-74-128-149
EPS-0.01-0.54-4.67-0.21-0.09-0.60-0.270.00-0.45-0.42-0.72-0.84
Key Financials TTM            
Total Revenue TTM2,9402,8282,7592,6922,6122,5352,5002,4062,3012,2002,0842,005
Ebitda TTM-774-792-8022357-417-70-229-315-418-518
Operating Income TTM-151-167-179-209-181-240-214-262-401-478-578-684
Net Income TTM-1,005-1,020-1,029-214-175-240-204-282-432-517-624-716
Growth Rates Quarterly            
Total Revenue Growth16.0%10.9%10.3%12.8%12.4%5.8%17.0%20.1%19.3%23.8%16.7%14.6%
EBITDA Growth52.3%20.4%-7984.0%-57.2%234.2%-74.9%113.5%160.1%76.7%79.1%56.7%18.0%
Operating Income Growth88.1%12.2%43.8%-404.4%76.3%-32.6%41.3%105.2%50.0%56.5%47.9%6.8%
Net Income Growth92.5%8.2%-1637.3%-4915.6%80.5%-48.7%61.0%100.5%51.2%59.0%42.1%10.9%
Margins Quarterly            
EBITDA Margin6.6%-5.4%-114.2%3.6%5.0%-7.5%1.6%9.5%-4.2%-4.5%-13.8%-19.0%
Operating Income Margin-0.3%-12.7%-5.3%-2.9%-2.6%-16.0%-10.5%1.1%-12.3%-12.8%-20.9%-25.3%
Net Income Margin-0.1%-14.3%-121.2%-5.4%-2.3%-17.3%-7.7%0.1%-13.0%-12.3%-23.1%-28.4%
Cash & Debt            
Total Cash8587861,0381,021947652778734776699632669
Total Debt2,5212,5212,7552,7582,7622,5552,5552,5622,5602,5652,4472,446
Net Debt / (Cash)1,6631,7351,7171,7371,8151,9031,7771,8271,7841,8661,8151,777
Cash Flows Quarterly            
FCF from Operations893147139107-827024100-3852-41
Cash Flows TTM            
FCF from Operations TTM30632421123311911215613973-88-224-300
Returns to Shareholders Quarterly            
Dividends000000000000
Share Repurchases-0-0-0-0-0-0-0-0-0-0-0-0
Return on Invested Capital (ROIC) Quarterly            
ROIC-0.1%-4.1%-1.7%-1.0%-0.8%-4.7%-3.2%0.2%-3.7%-3.7%-5.6%-6.5%
Return on Invested Capital (ROIC) TTM            
ROIC TTM-1.7%-1.9%-2.1%-2.4%-2.1%-2.8%-2.6%-3.1%-4.8%-5.7%-7.0%-8.4%

Segment Financials

Revenue by Segment

$ Mil20242023202220212020
Development and global commercialization of clinical laboratory services2,5002,084   
COVID-19 Testing  143236 
Commercial  750596398
International  1107711
Medicare parts B & C  636523429
Other  1286038
Total2,5002,0841,7671,491876


Net Income by Segment
$ Mil20242023202220212020
Development and global commercialization of clinical laboratory services-204-624   
Total-204-624   


Price Behavior

EXAS Betas & Captures as of 8/31/2025

 1M2M3M6M1Y3Y
Beta-0.23-0.16-0.090.890.791.13
Up Beta-1.51-0.89-1.001.180.851.20
Down Beta-2.66-2.35-1.000.540.590.91
Up Capture84%5%-9%68%51%145%
Bmk +ve Days10223571142415
Stock +ve Days13202761111354
Down Capture99%212%148%89%103%104%
Bmk -ve Days11192754106334
Stock -ve Days8213564137392

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Short Interest

Short Interest: As Of Date8292025
Short Interest: Shares Quantity7,336,134
Short Interest: % Change Since 8152025-22.5%
Average Daily Volume2,513,605
Days-to-Cover Short Interest2.92
Basic Shares Quantity188,902,000
Short % of Basic Shares3.9%

Returns Analyses

Earnings Returns History

Expand for More

 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
8/6/2025-8.0%-4.3%14.7%
5/1/20259.3%12.5%19.0%
2/19/2025-1.9%-3.9%-12.3%
11/5/2024-23.5%-29.9%-12.4%
7/31/202426.8%22.6%36.3%
5/8/2024-9.0%-10.3%-27.8%
2/21/2024-6.0%-11.0%-2.0%
11/1/2023-1.7%-1.1%5.5%
...
SUMMARY STATS   
# Positive71010
# Negative161313
Median Positive10.9%12.2%13.0%
Median Negative-5.3%-10.2%-12.4%
Max Positive26.8%35.9%40.8%
Max Negative-23.5%-29.9%-27.8%

SEC Filings

Expand for More

Report DateFiling DateFiling
6302025806202510-Q 6/30/2025
3312025501202510-Q 3/31/2025
12312024219202510-K 12/31/2024
93020241105202410-Q 9/30/2024
6302024731202410-Q 6/30/2024
3312024508202410-Q 3/31/2024
12312023221202410-K 12/31/2023
93020231101202310-Q 9/30/2023
6302023801202310-Q 6/30/2023
3312023509202310-Q 3/31/2023
12312022221202310-K 12/31/2022
93020221103202210-Q 9/30/2022
6302022802202210-Q 6/30/2022
3312022426202210-Q 3/31/2022
12312021222202210-K 12/31/2021
93020211102202110-Q 9/30/2021

Insider Activity

Expand for More

 OwnerTitleFiling DateActionPriceSharesTransacted
Value		Value of
Held Shares		Form
0Doyle James Edward 8142025Sell42.021,48562,4002,519,603Form
1Conroy Kevin TPresident and CEO11132024Buy51.3519,5001,001,32555,159,708Form
2Baranick BrianEVP, GM, Precision Oncology10092024Sell70.0092965,030893,060Form
3Baranick BrianEVP, GM, Precision Oncology9192024Sell70.0092965,030958,090Form

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.